AZD1390

Overview

AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC 50 of 0.78 nM in cell.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > ATM/ATR

Product Information

• Catalog No.: HY-109566
• CAS No.: 2089288-03-7
• Molecular Formula: C27H32FN5O2
• Molecular Weight: 477.57
• Purity: 99.22%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: 5 mg/mL (10.47 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source